These RAS mutations, identified using the CRC RAScan kits, which use Surveyor®-Wave® technology, provide physicians with important information regarding tumor mutation status to help with clinical treatment decisions for their mCRC patients.
The company’s CLIA-certified laboratory in the United States is available immediately to receive patient samples for testing.
The kit was developed in collaboration with Amgen Inc, and follows discovery of RAS (KRAS and NRAS) mutations in a predefined-retrospective subset analysis of a global, multicenter, randomized Phase 3 study. Results of this analysis will be presented at the 2013 ASCO Annual Meeting on June 4 (Abstract Number 3511; 8:00 am to 12:00 pm CDT, S405).
“Our partnership with Amgen, and development of CRC RAScan, supports our goal of developing predictive tests that can help physicians make decisions when selecting treatment options for patients,” says Craig Tuttle, CEO, Transgenomic. “CRC RAScan is the only dedicated test available today that identifies the full range of RAS mutations to help with treatment decisions for patients with metastatic colorectal cancer.”
For more information about how to order a CRC RAScan test or to obtain a mutation detection test kit, call (888) 813-7253 or send an e-mail.
[Source: Transgenomic Inc]